Monday, July 24, 2000
The structural and chemical makeup of nucleic acids often limits the industrial and therapeutic applications of DNA. In particular, gene chips and nucleic acid-based therapeutics such as antisense require DNA strands to have properties such as high affinity binding, stability and bioavailablity in order to be effective.
Annovis Inc. is looking to supply companies with improved forms of DNA using its nucleic acid modification technologies. Annovis' modified nucleic acid mimetics include changes in the structure of the backbone, the sugar moiety, and/or the base in DNA or RNA.